"A Phase IIb clinical trial found that ION224, a drug blocking the DGAT2 enzyme, improves liver health in patients with MASH. Approximately 60% of patients receiving the highest dose showed meaningful improvements. The drug targets the root cause of fat accumulation in the liver."